Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph early_phase_1
1
33%
Ph phase_1
2
67%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 1Safety & dosage
2(66.7%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Not yet recruiting3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Early Phase 11 (33.3%)
Phase 12 (66.7%)

Trials by Status

not_yet_recruiting3100%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingearly_phase_1

RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas

NCT07563543
not_yet_recruitingphase_1

RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas

NCT07506668
not_yet_recruitingphase_1

A Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas

NCT07316920

Clinical Trials (3)

Showing 3 of 3 trials
NCT07563543Early Phase 1

RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas

Not Yet Recruiting
NCT07506668Phase 1

RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas

Not Yet Recruiting
NCT07316920Phase 1

A Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas

Not Yet Recruiting

All 3 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
3